We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Pseudoprogression as an adverse event of glioblastoma therapy.
- Authors
Balaña, Carmen; Capellades, Jaume; Pineda, Estela; Estival, Anna; Puig, Josep; Domenech, Sira; Verger, Eugenia; Pujol, Teresa; Martinez‐García, Maria; Oleaga, Laura; Velarde, JoseMaria; Mesia, Carlos; Fuentes, Rafael; Marruecos, Jordi; Del Barco, Sonia; Villà, Salvador; Carrato, Cristina; Gallego, Oscar; Gil‐Gil, Miguel; Craven‐Bartle, Jordi
- Abstract
We explored predictive factors of pseudoprogression (PsP) and its impact on prognosis in a retrospective series of uniformly treated glioblastoma patients. Patients were classified as having PsP, early progression ( eP) or neither ( nP). We examined potential associations with clinical, molecular, and basal imaging characteristics and compared overall survival ( OS), progression-free survival ( PFS), post-progression survival ( PPS) as well as the relationship between PFS and PPS in the three groups. Of the 256 patients studied, 56 (21.9%) were classified as PsP, 70 (27.3%) as eP, and 130 (50.8%) as nP. Only MGMT methylation status was associated to PsP. MGMT methylated patients had a 3.5-fold greater possibility of having PsP than eP ( OR: 3.48; 95% CI: 1.606-7.564; P = 0.002). OS was longer for PsP than eP patients (18.9 vs. 12.3 months; P = 0.0001) but was similar for PsP and nP patients ( P = 0.91). OS was shorter-though not significantly so-for PsP than nP patients ( OS: 19.5 vs. 27.9 months; P = 0.63) in methylated patients. PPS was similar for patients having PsP, eP or nP ( PPS: 7.2 vs. 5.4 vs. 6.7; P = 0.43). Neurological deterioration occurred in 64.3% of cases at the time they were classified as PsP and in 72.8% of cases of eP ( P = 0.14). PsP confounds the evaluation of disease and does not confer a survival advantage in glioblastoma.
- Subjects
GLIOBLASTOMA multiforme; GLIOBLASTOMA multiforme treatment; ADVERSE health care events; PROGRESSION-free survival; METHYLATION; PATIENTS
- Publication
Cancer Medicine, 2017, Vol 6, Issue 12, p2858
- ISSN
2045-7634
- Publication type
Article
- DOI
10.1002/cam4.1242